YnetnewsEconomy
Teva Expands US Biosimilar Offerings Through Samsung Bioepis Partnership
Summarized from Ynetnews by baba
CenterNeutral tone
Teva Pharmaceutical Industries has partnered with Samsung Bioepis to market two biosimilar drugs, infliximab-abda and ETICOVO, in the United States. The deal expands Teva's immunology portfolio with treatments for inflammatory and autoimmune diseases. Samsung Bioepis will continue manufacturing, while Teva will handle U.S. commercialization, with rights transferring in 2026 and 2027. The agreement is part of Teva's growth strategy, building on previous collaborations between the two companies.
The story in 6 lines · by baba
- Teva and Samsung Bioepis will co-market two biosimilar drugs in the U.S.
- The deal includes infliximab-abda (Remicade biosimilar) and ETICOVO (Enbrel biosimilar).
- Teva gains U.S. commercialization rights, with transfers expected by late 2026 and Q3 2027.
- Samsung Bioepis will continue manufacturing and regulatory oversight for the drugs.
- The agreement expands Teva's immunology portfolio and strengthens its partnership with Samsung Bioepis.
- Financial terms include upfront payments, potential sales-based bonuses, and profit sharing.
Ynetnews publishes in English. The key points are summarized above. Read Ynetnews’s full report from the link at the top of the page.